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Kontrol Mean .5560 .00812 
95% Confidence 
Interval for Mean 
Lower Bound .5334  
Upper Bound .5786  
5% Trimmed Mean .5556  
Median .5500  
Variance .000  
Std. Deviation .01817  
Minimum .54  
Maximum .58  
Range .04  
Interquartile Range .03  
Skewness .567 .913 
Kurtosis -2.231 2.000 
Perlakuan 1 Mean .6400 .04817 
95% Confidence 
Interval for Mean 
Lower Bound .5063  
Upper Bound .7737  
5% Trimmed Mean .6400  
Median .6100  
Variance .012  
Std. Deviation .10770  
Minimum .51  
Maximum .77  




Valid Missing Total 




Kontrol 5 100.0% 0 0.0% 5 100.0% 
Perlakuan 1 5 100.0% 0 0.0% 5 100.0% 
Perlakuan 2 5 100.0% 0 0.0% 5 100.0% 
Perlakuan 3 5 100.0% 0 0.0% 5 100.0% 
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Range .26  
Interquartile Range .21  
Skewness .162 .913 
Kurtosis -1.956 2.000 
Perlakuan 2 Mean .6520 .04329 
95% Confidence 
Interval for Mean 
Lower Bound .5318  
Upper Bound .7722  
5% Trimmed Mean .6489  
Median .6600  
Variance .009  
Std. Deviation .09680  
Minimum .56  
Maximum .80  
Range .24  
Interquartile Range .17  
Skewness .881 .913 
Kurtosis .496 2.000 
Perlakuan 3 Mean .6340 .02960 
95% Confidence 
Interval for Mean 
Lower Bound .5518  
Upper Bound .7162  
5% Trimmed Mean .6322  
Median .6200  
Variance .004  
Std. Deviation .06618  
Minimum .56  
Maximum .74  
Range .18  
Interquartile Range .10  
Skewness 1.106 .913 















Kontrol .229 5 .200* .867 5 .254 
Perlakuan 1 .210 5 .200* .941 5 .677 
Perlakuan 2 .226 5 .200* .900 5 .409 
Perlakuan 3 .264 5 .200* .919 5 .522 
 
*. This is a lower bound of the true significance. 










Test of Homogeneity of Variances 
Kadar Kreatinin Serum   
Levene Statistic df1 df2 Sig. 




Kadar Kreatinin Serum   
 Sum of Squares df Mean Square F Sig. 
Between Groups .029 3 .010 1.484 .257 
Within Groups .103 16 .006   
Total .131 19    
 
 
Post Hoc Tests 
 
Multiple Comparisons 
Dependent Variable:   Kadar Kreatinin Serum   















Kontrol Perlakuan 1 -.08400 .05068 .117 -.1914 .0234 
Perlakuan 2 -.09600 .05068 .076 -.2034 .0114 
Perlakuan 3 -.07800 .05068 .143 -.1854 .0294 
Perlakuan 1 Kontrol .08400 .05068 .117 -.0234 .1914 
Perlakuan 2 -.01200 .05068 .816 -.1194 .0954 
Perlakuan 3 .00600 .05068 .907 -.1014 .1134 
Perlakuan 2 Kontrol .09600 .05068 .076 -.0114 .2034 
Perlakuan 1 .01200 .05068 .816 -.0954 .1194 
Perlakuan 3 .01800 .05068 .727 -.0894 .1254 
Perlakuan 3 Kontrol .07800 .05068 .143 -.0294 .1854 
Perlakuan 1 -.00600 .05068 .907 -.1134 .1014 
Perlakuan 2 -.01800 .05068 .727 -.1254 .0894 
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